Holen Sie sich die Stockscreener-App
4.445
8.07%
-0.39
Handel nachbörslich:
4.48
0.035
+0.79%
Schlusskurs vom Vortag:
$4.835
Offen:
$4.84
24-Stunden-Volumen:
5.88M
Relative Volume:
2.01
Marktkapitalisierung:
$557.07M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-110.78M
KGV:
-5.1092
EPS:
-0.87
Netto-Cashflow:
$-75.59M
1W Leistung:
-19.47%
1M Leistung:
-11.63%
6M Leistung:
-29.78%
1J Leistung:
+76.39%
1-Tages-Spanne:
$4.26
$4.84
1-Wochen-Bereich:
$4.26
$5.54
52-Wochen-Spanne:
$2.43
$9.97
Humacyte Inc Stock (HUMA) Company Profile
Firmenname
Humacyte Inc
Sektor
Branche
Telefon
919-313-9633
Adresse
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
Vergleichen Sie HUMA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| HUMA | 4.445 | 557.07M | 0 | -110.78M | -75.59M | -0.87 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-08-14 | Hochstufung | Piper Sandler | Underweight → Neutral |
| 2023-06-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-05-16 | Herabstufung | Piper Sandler | Overweight → Underweight |
| 2021-10-29 | Eingeleitet | Cowen | Outperform |
| 2021-09-24 | Eingeleitet | Oppenheimer | Outperform |
| 2021-09-22 | Eingeleitet | BTIG Research | Buy |
| 2021-09-16 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Humacyte Inc Aktie (HUMA) Neueste Nachrichten
Humacyte (HUMA) Faces Class Action Lawsuit After FDA Inspection Reveals Manufacturing Issues– Hagens Berman - GlobeNewswire
HUMA CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Humacyte, Inc. - Business Wire
Humacyte Presents Preclinical Results of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting at American Heart Association's Scientific Sessions 2024 - The Manila Times
Humacyte’s (HUMA) Statements to Investors Called Into Question in Light of FDA Violations – Hagens Berman - GlobeNewswire
Humacyte’s (HUMA) Statements to Investors Called Into Question in Light of FDA Violations – Hagens Berman - GlobeNewswire Inc.
Humacyte, Inc. (HUMA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - AccessWire
HC Wainwright Decreases Earnings Estimates for Humacyte - MarketBeat
Humacyte Advances with $15M Direct Offering - TipRanks
Cantor Fitzgerald Reduces Earnings Estimates for Humacyte - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Humacyte, Inc. (HUMA) Shareholders to Inquire about Securities Investigation - AccessWire
Humacyte Announces Pricing of $15.0 Million Registered Direct Offering - The Manila Times
Humacyte's (HUMA) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
HUMACYTE ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Humacyte, Inc. (HUMA) And Encourages Shareholders to Reach Out - AccessWire
Humacyte (HUMA) Faces Questions After FDA Inspection – Hagens Berman - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Encourages Humacyte, Inc. (HUMA) Stockholders to Inquire about Securities Investigation - AccessWire
Humacyte, Inc. (NASDAQ:HUMA) Q3 2024 Earnings Call Transcript - Insider Monkey
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Humacyte, Inc.HUMA - cnhinews.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Humacyte, Inc. (HUMA) and Encourages Investors to Learn More About the Investigation - AccessWire
Humacyte (NASDAQ:HUMA) Shares Up 11%Time to Buy? - MarketBeat
Humacyte Reports Q3 2024 Results Amid FDA Review - TipRanks
Humacyte Inc (HUMA) Quarterly 10-Q Report - Quartz
Humacyte Third Quarter 2024 Financial Results and Business Update - WICZ
Objective long/short (HUMA) Report - Stock Traders Daily
Humacyte, Inc. (HUMA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - AccessWire
Research Analysts Offer Predictions for Humacyte Q3 Earnings - MarketBeat
Humacyte (HUMA) to Release Quarterly Earnings on Friday - MarketBeat
The Law Offices of Frank R. Cruz Continues Its Investigation of Humacyte, Inc. (HUMA) on Behalf of Investors - Business Wire
Analysts Issue Forecasts for Humacyte FY2028 Earnings - MarketBeat
Humacyte to Present Third Quarter Financial Results and Provide Corporate Update on November 8, 2024 - The Manila Times
Bronstein, Gewirtz & Grossman, LLC Encourages Humacyte, Inc. (HUMA) Investors to Inquire about Securities Investigation - AccessWire
HC Wainwright Forecasts Strong Price Appreciation for Humacyte (NASDAQ:HUMA) Stock - MarketBeat
Humacyte (NASDAQ:HUMA) Trading Down 5%Here's Why - MarketBeat
Humacyte wins special advanced-therapy designation for ATEV - MSN
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Humacyte, Inc. (HUMA) And Encourages Stockholders to Reach Out - AccessWire
2024-11-03 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Humacyte, Inc. (HUMA) And Encourages Stockholders to Reach Out | NDAQ:HUMA | Press Release - Stockhouse Publishing
Humacyte, Inc. (HUMA) Declines More Than Market: Some Information for Investors - MSN
Humacyte (NASDAQ:HUMA) Trading 7.5% HigherHere's What Happened - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating Humacyte, Inc. (HUMA) And Encourages Stockholders to Connect - AccessWire
Humacyte, Inc. (HUMA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - AccessWire
Humacyte StockInvestors of Humacyte Encouraged to Contact Kehoe Law Firm, P.C.HUMA - AccessWire
Revisiting Humacyte (NASDAQ:HUMA) - Seeking Alpha
Humacyte, Inc. (NASDAQ:HUMA) Receives $10.00 Consensus Target Price from Analysts - MarketBeat
Peripheral Artery Disease MARKET TO WITNESS UPSURGE IN GROWTH - openPR
Humacyte's SWOT analysis: HAV tech stock poised for growth amid challenges - Investing.com Canada
(HUMA) Trading Signals - Stock Traders Daily
Humacyte (NASDAQ:HUMA) Stock Price Down 2.9%Here's Why - MarketBeat
Humacyte reports positive trial results for hemodialysis access By Investing.com - Investing.com Canada
Humacyte reports positive trial results for hemodialysis access - Investing.com India
Humacyte Announces Presentation of Positive Results from V007 Phase 3 AV Access Clinical Trial at the American Society of Nephrology's Kidney Week 2024 - The Manila Times
Humacyte, Inc. (HUMA) Laps the Stock Market: Here's Why - MSN
Finanzdaten der Humacyte Inc-Aktie (HUMA)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):